Imatinib (Gleevec) inhibits ABL and other tyrosine kinases by binding to their catalytic domains and has become a standard therapy against BCR‐ABL + CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.